This NDC is on FDA's drug shortage list (posted Jul 18, 2023)
Reported reason: Discontinuation of the manufacture of the drug
Product Information
SAXENDA 18 MG/3 ML PEN is a brand product labeled by Novo Nordisk, priced at $87.1260 per ML under NDC 00169280015. Its NADAC has been published 568 times since Nov 18, 2015.
FDA first approved this application on Dec 23, 2014. Its Orange Book therapeutic-equivalence code is AP2.
The High Outlier badge above means this manufacturer's average price in the liraglutide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
6 mg/mL
Manufacturer
Novo NordiskNDC
00169280015
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
LIRAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA206321FDA Approved
12/23/2014
TE Code
AP2
On Market Since
12/31/2014
Pharmacological Classes
Price Statistics
The NADAC for SAXENDA 18 MG/3 ML PEN has been published 568 times since Nov 18, 2015, and over the history we have for it it has risen 25.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $87.1260 per ML |
|---|---|
| All-time high | $87.1688 (Aug 12, 2026) |
| All-time low | $69.2275 (Nov 18, 2015) |
| 52-week high | $87.1688 |
| 52-week low | $86.9627 |
| Median price | $86.2389 |
| Average price | $82.0678 |
| Largest weekly change | +8.0% (Apr 13, 2016) |
| Weeks tracked | 568 |
| Tracking since | Nov 18, 2015 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 65% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
liraglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAXENDA 18 MG/3 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for SAXENDA 18 MG/3 ML PEN, manufactured by Novo Nordisk, is $87.1260 per ML (NDC 00169280015), effective Sep 30, 2026.
How has the price of SAXENDA 18 MG/3 ML PEN changed over time?
Over the history we have for it, the NADAC for SAXENDA 18 MG/3 ML PEN has risen 25.9%. It has been tracked across 568 weekly CMS publications since Nov 18, 2015.
What are the highest and lowest recorded NADAC prices for SAXENDA 18 MG/3 ML PEN?
Since Nov 18, 2015, the NADAC for SAXENDA 18 MG/3 ML PEN has ranged from a low of $69.2275 (Nov 18, 2015) to a high of $87.1688 (Aug 12, 2026), with a median of $86.2389 per ML.
Are there cheaper alternatives to SAXENDA 18 MG/3 ML PEN?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIRAGLUTIDE 3-PAK 18 MG/3 ML, is $30.6324 per ML — about 65% below SAXENDA 18 MG/3 ML PEN.
Who manufactures SAXENDA 18 MG/3 ML PEN?
SAXENDA 18 MG/3 ML PEN (NDC 00169280015) is labeled by Novo Nordisk, and CMS classifies it as a brand product.
Is SAXENDA 18 MG/3 ML PEN in shortage?
Yes — NDC 00169280015 is currently listed in FDA's drug shortage database (posted Jul 18, 2023). Reported reason: Discontinuation of the manufacture of the drug.